These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 25500206)

  • 1. Etiology of angiogenesis inhibition-related hypertension.
    Lankhorst S; Saleh L; Danser AJ; van den Meiracker AH
    Curr Opin Pharmacol; 2015 Apr; 21():7-13. PubMed ID: 25500206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypertension during vascular endothelial growth factor inhibition: focus on nitric oxide, endothelin-1, and oxidative stress.
    Lankhorst S; Kappers MH; van Esch JH; Danser AH; van den Meiracker AH
    Antioxid Redox Signal; 2014 Jan; 20(1):135-45. PubMed ID: 23458507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelin-1 and antiangiogenesis.
    Lankhorst S; Danser AH; van den Meiracker AH
    Am J Physiol Regul Integr Comp Physiol; 2016 Feb; 310(3):R230-4. PubMed ID: 26511523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system.
    Kappers MH; Smedts FM; Horn T; van Esch JH; Sleijfer S; Leijten F; Wesseling S; Strevens H; Jan Danser AH; van den Meiracker AH
    Hypertension; 2011 Aug; 58(2):295-302. PubMed ID: 21670421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1.
    Lankhorst S; Kappers MH; van Esch JH; Danser AH; van den Meiracker AH
    J Hypertens; 2013 Mar; 31(3):444-54; discussion 454. PubMed ID: 23221987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.
    Kruzliak P; Novák J; Novák M
    Am J Hypertens; 2014 Jan; 27(1):3-13. PubMed ID: 24168915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects.
    Kappers MH; van Esch JH; Sleijfer S; Danser AH; van den Meiracker AH
    J Hypertens; 2009 Dec; 27(12):2297-309. PubMed ID: 19680138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic-induced hypertension: the molecular basis of signaling network.
    Nagai A; Sado T; Naruse K; Noguchi T; Haruta S; Yoshida S; Tanase Y; Tsunemi T; Kobayashi H
    Gynecol Obstet Invest; 2012; 73(2):89-98. PubMed ID: 22222493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.
    Izzedine H; Rixe O; Billemont B; Baumelou A; Deray G
    Am J Kidney Dis; 2007 Aug; 50(2):203-18. PubMed ID: 17660022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Antihypertensive Drugs in Neoplastic Patients.
    Rizzoni D; De Ciuceis C; Porteri E; Agabiti-Rosei C; Agabiti-Rosei E
    High Blood Press Cardiovasc Prev; 2017 Jun; 24(2):127-132. PubMed ID: 28361339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitric oxide and adverse events of vascular endothelial growth factor inhibitors.
    Thachil J
    Curr Med Res Opin; 2011 Aug; 27(8):1503-7. PubMed ID: 21651424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension.
    Versmissen J; Mirabito Colafella KM; Koolen SLW; Danser AHJ
    Cardiovasc Res; 2019 Apr; 115(5):904-914. PubMed ID: 30726882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker.
    Robinson ES; Khankin EV; Karumanchi SA; Humphreys BD
    Semin Nephrol; 2010 Nov; 30(6):591-601. PubMed ID: 21146124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of cyclo-oxygenase 1 and 2 inhibition on angiogenesis inhibitor-induced hypertension and kidney damage.
    Mirabito Colafella KM; van Dorst DCH; Neuman RI; Doorn LV; Neves KB; Montezano AC; Garrelds IM; van Veghel R; de Vries R; Uijl E; Clahsen-van Groningen MC; Baelde HJ; van den Meiracker AH; Touyz RM; Visser W; Danser AHJ; Versmissen J
    Clin Sci (Lond); 2022 May; 136(9):675-694. PubMed ID: 35441670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbon monoxide ameliorates renal cold ischemia-reperfusion injury with an upregulation of vascular endothelial growth factor by activation of hypoxia-inducible factor.
    Faleo G; Neto JS; Kohmoto J; Tomiyama K; Shimizu H; Takahashi T; Wang Y; Sugimoto R; Choi AM; Stolz DB; Carrieri G; McCurry KR; Murase N; Nakao A
    Transplantation; 2008 Jun; 85(12):1833-40. PubMed ID: 18580478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs).
    Cosmai L; Gallieni M; Liguigli W; Porta C
    J Nephrol; 2017 Apr; 30(2):171-180. PubMed ID: 27154025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelial-specific Notch blockade inhibits vascular function and tumor growth through an eNOS-dependent mechanism.
    Patenaude A; Fuller M; Chang L; Wong F; Paliouras G; Shaw R; Kyle AH; Umlandt P; Baker JH; Diaz E; Tong J; Minchinton AI; Karsan A
    Cancer Res; 2014 May; 74(9):2402-11. PubMed ID: 24599126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The role and clinical importance of nitric oxide-endothelin system in hypertension].
    Katona E; Juhász M; Varga Z; Paragh G; Fülesdi B; Páll D
    Orv Hetil; 2006 Sep; 147(38):1819-24. PubMed ID: 17066598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of ATP-sensitive potassium channels protects vascular endothelial cells from hypertension and renal injury induced by hyperuricemia.
    Long CL; Qin XC; Pan ZY; Chen K; Zhang YF; Cui WY; Liu GS; Wang H
    J Hypertens; 2008 Dec; 26(12):2326-38. PubMed ID: 19008712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vanillic acid prevents the deregulation of lipid metabolism, endothelin 1 and up regulation of endothelial nitric oxide synthase in nitric oxide deficient hypertensive rats.
    Kumar S; Prahalathan P; Saravanakumar M; Raja B
    Eur J Pharmacol; 2014 Nov; 743():117-25. PubMed ID: 25239071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.